|
PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab. |
|
Isabelle Laure Ray-Coquard |
Honoraria - AstraZeneca; PharmaMar; Roche |
Consulting or Advisory Role - Abbvie; Amgen; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; pharmamar; Roche |
Consulting or Advisory Role - AstraZeneca; Pfizer; PharmaMar; Roche; tesaro |
Research Funding - MSD (Inst); Pfizer (Inst); Roche |
|
|
Honoraria - Asahi Kasei; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen Oncology; Kyowa Hakko Kirin; Lilly Japan; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical |
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Pfizer; Taiho Pharmaceutical |
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Kaken Pharmaceutical (Inst); Lilly (Inst); MSD (Inst); Oncotherapeutics (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca |
|
|
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Tesaro |
|
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; MSD Oncology; Pfizer; PharmaMar; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Roche; SOBI |
Consulting or Advisory Role - AstraZeneca; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche |
Speakers' Bureau - AstraZeneca; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Roche |